Separate terms with OR to return results that match either term.
 
Clear All

640 Matching ResultsExport these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year (Ascending) FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
C9110 Alemtuzumab Lemtrada 10 mg Immunotherapy Monoclonal Antibody CD52 No 2001 Jan. 1, 2001 Dec. 31, 2007 No Longer Used
S0146 Peginterferon Alfa-2b Pegintron, Sylatron 20 mcg/mL Immunotherapy Cytokine Interferon No 2001 July 1, 2005 Sept. 30, 2010 No Longer Used
J0881 Darbepoetin alfa Aranesp 1 mcg Ancillary Therapy Erythropoiesis-Stimulating Agent No 2001 Jan. 1, 2006 In Use
J3487 Zoledronic acid Zometa (4 mg/5 ml) 1 mg Ancillary Therapy Bisphosphonate No 2001 Jan. 1, 2003 Dec. 31, 2013 No Longer Used
J3489 Zoledronic acid Zometa (4 mg/5 ml) 1 mg Ancillary Therapy Bisphosphonate No 2001 Jan. 1, 2014 In Use
Q2051 Zoledronic acid Zometa (4 mg/5 ml) 1 mg Ancillary Therapy Bisphosphonate No 2001 July 1, 2013 Jan. 1, 2014 No Longer Used
C9205 Oxaliplatin Eloxatin unspecified Chemotherapy Alkylating Agent Platinum Compound No 2002 July 1, 2003 Dec. 31, 2005 No Longer Used
J9263 Oxaliplatin Eloxatin 0.5 mg Chemotherapy Alkylating Agent Platinum Compound No 2002 Jan. 1, 2004 In Use
C9117 Ibritumomab tiuxetan Zevalin Per MCI Immunotherapy Radioimmunotherapy CD20 No 2002 Oct. 1, 2002 Dec. 31, 2002 No Longer Used
C9118 Ibritumomab tiuxetan Zevalin Per MCI Immunotherapy Radioimmunotherapy CD20 No 2002 Oct. 1, 2002 Dec. 31, 2002 No Longer Used

Found 640 results in 2 millisecondsExport these results

The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.